NewsJun 2, 2026
Legend Biotech Presents Promising CARVYKTI and LB2102 Data at ASCO
Legend Biotech has presented significant new data at ASCO 2026, showcasing updated survival and safety results for its multiple myeloma therapy CARVYKTI from the CARTITUDE-4 study. The company also unveiled first-in-human data for its investigational CAR-T cell therapy, LB2102, targeting solid tumors.
Dr. Sarah Mitchell
